keyword
MENU ▼
Read by QxMD icon Read
search

Levonorgestrel

keyword
https://www.readbyqxmd.com/read/28219738/ulipristal-acetate-administration-at-mid-cycle-changes-gene-expression-profiling-of-endometrial-biopsies-taken-during-the-receptive-period-of-the-human-menstrual-cycle
#1
Saúl Lira-Albarrán, Marta Durand, Marco F Larrea-Schiavon, Leticia González, David Barrera, Claudia Vega, Armando Gamboa-Domínguez, Claudia Rangel, Fernando Larrea
The aim of this study was to analyze the effects of mid-cycle administration of Ulipristal acetate (UPA) on gene expression in endometrial biopsies taken during the receptive phase of the cycle. Fourteen healthy menstruating women were studied during 14 control non-treated and 12 treated cycles with a single dose of 30 mg UPA when follicle diameter reached 20 mm. Ovulation in both treated and control cycles was confirmed by serial determinations of serum LH, progesterone and vaginal ultrasound. An endometrial biopsy at day LH+7, in each cycle, was taken for RNA microarray and qPCR analysis or prepared for histological and immunohistochemistry studies...
February 17, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28209488/postoperative-maintenance-levonorgestrel-releasing-intrauterine-system-and-endometrioma-recurrence-a-randomized-controlled-study
#2
Yi-Jen Chen, Teh-Fu Hsu, Ben-Shian Huang, Hsiao-Wen Tsai, Yen-Hou Chang, Peng-Hui Wang
BACKGROUND: According to three randomized trials, levonorgestrel-releasing intrauterine system significantly reduced recurrent endometriosis- related pelvic pain at postoperative year 1. Only a few studies have evaluated the long-term effectiveness of the devicefor preventing endometrioma recurrence, and the effects of a levonorgestrel-releasing intrauterine system as a maintenance therapy remain unclear. OBJECTIVES: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing postoperative endometrioma recurrence...
February 13, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28189123/impact-of-various-progestins-with-or-without-transdermal-testosterone-on-gonadotropin-levels-for-non-invasive-hormonal-male-contraception-a-randomized-clinical-trial
#3
M Zitzmann, J Rohayem, J Raidt, S Kliesch, N Kumar, R Sitruk-Ware, E Nieschlag
Although several progestins have been tested for hormonal male contraception, the effects of dosage and nature of various progestins on gonadotropin suppression combined with and without additional testosterone has not been performed in a comparative trial. The aim of this study was to evaluate the differential impact of four oral or transdermal progestins on the suppression of gonadotropins in healthy men: oral: cyproterone acetate (CPA), levonorgestrel (LNG), norethisterone acetate (NETA), and transdermal: Nestorone(®) (NES), all in combination with transdermal testosterone (T)...
February 11, 2017: Andrology
https://www.readbyqxmd.com/read/28188772/two-year-continuation-of-intrauterine-devices-and-contraceptive-implants-in-a-mixed-payer-setting-a-retrospective-review
#4
Jessica N Sanders, David K Turok, Lori M Gawron, Amy Law, Lonnie Wen, Richard Lynen
BACKGROUND: As the popularity of long-acting reversible contraception increases, so does the need for accurate data on method continuation in diverse clinical settings. We determined two-year continuation rates for the levonorgestrel 52mg intrauterine device, the copper T380A intrauterine device, and the 68mg etonogestrel contraceptive implant in an academic healthcare system with mixed-payer reimbursement. OBJECTIVE(S): To examine the proportion and characteristics of women who continue IUD and implant use to two years and relate continuation to device type when controlling for patient characteristics...
February 8, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28187506/the-effect-of-gene-variants-on-levonorgestrel-pharmacokinetics-when-combined-with-antiretroviral-therapy-containing-efavirenz-or-nevirapine
#5
M Neary, M Lamorde, A Olagunju, K M Darin, C Merry, P Byakika-Kibwika, D J Back, M Siccardi, A Owen, K K Scarsi
Reduced levonorgestrel concentrations from the levonorgestrel contraceptive implant was previously seen when given concomitantly with efavirenz. We sought to assess whether single nucleotide polymorphisms (SNPs) in genes involved in efavirenz and nevirapine metabolism were linked to these changes in levonorgestrel concentration. SNPs in CYP2B6, CYP2A6, NR1I2 and NR1I3 were analysed. Associations of participant demographics and genotype with levonorgestrel pharmacokinetics were evaluated in HIV-positive women using the levonorgestrel implant plus efavirenz- or nevirapine-based ART, in comparison to ART-naïve women using multivariate linear regression...
February 10, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28179523/progesterone-based-contraceptives-reduce-adaptive-immune-responses-and-protection-against-sequential-influenza-a-virus-infections
#6
Olivia J Hall, Raffael Nachbagauer, Meghan S Vermillion, Ashley L Fink, Vanessa Phuong, Florian Krammer, Sabra L Klein
In addition to their intended use, progesterone (P4)-based contraceptives promote anti-inflammatory immune responses, yet their effects on the outcome of infectious diseases, including influenza A virus (IAV), are rarely evaluated. To evaluate their impact on immune responses to sequential IAV infections, adult female mice were treated with placebo or one of two progestins, P4 or levonorgestrel (LNG), and infected with mouse adapted (ma) H1N1 virus. Treatment with P4 or LNG reduced morbidity, but had no effect on pulmonary virus titers, during primary H1N1 infection as compared to placebo treatment...
February 8, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28176932/intrauterine-levonorgestrel-delivery-with-frameless-fibrous-delivery-system-review-of-clinical-experience
#7
REVIEW
Dirk Wildemeersch, Amaury Andrade, Norman D Goldstuck, Thomas Hasskamp, Geert Jackers
The concept of using a frameless intrauterine device (IUD) instead of the conventional plastic framed IUD is not new. Frameless copper IUDs have been available since the late 1990s. They rely on an anchoring system to retain in the uterine cavity. The clinical experience with these IUDs suggests that frameless IUDs fit better as they are thin and, therefore, do not disturb or irritate the uterus. High tolerance and continuation rates have been achieved as complaints of pain are virtually nonexistent and the impact on menstrual blood loss is minimal...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28166594/influence-of-dyslipidemia-on-the-quality-of-sexual-life-in-women-in-the-menacme-using-a-combined-oral-contraceptive
#8
Rodolfo Strufaldi, Luciano Melo Pompei, Marcelo Luis Steiner, César Eduardo Fernandes
Purpose Female sexual dysfunction is a complex and common condition that affects women, and the relationship between sexual function and dyslipidemia is poorly studied. This study aims to assess this relationship in the reproductive life women in the menacme who use combined oral contraceptives (COCs). Methods A total of 49 healthy women who were sexually active received COC pills that contained ethinylestradiol 30 mcg (EE30) plus levonorgestrel 150 mcg (LNG150). The women were divided into two groups according to their lipid profiles...
December 2016: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/28147241/prolonged-use-of-the-etonogestrel-implant-and-levonorgestrel-intrauterine-device-two-years-beyond-fda-approved-duration
#9
Colleen McNicholas, Erin Swor, Leping Wan, Jeffrey F Peipert
BACKGROUND: The subdermal contraceptive implant, and the 52mg levonorgestrel intrauterine device (IUD) are currently FDA-approved for three and five years of use respectively. Limited available data has suggested both of these methods are effective beyond that time. Demonstration of prolonged effectiveness will improve the cost-effectiveness of the device, and potentially patient continuation and satisfaction. OBJECTIVE: To evaluate the effectiveness of the contraceptive implant and the 52-mg hormonal intrauterine device (IUD) in women using the method for two years beyond the current FDA-approved duration...
January 29, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28144464/effects-of-second-and-third-generation-oral-contraceptives-on-lipid-and-carbohydrate-metabolism-in-overweight-and-obese-women-a-randomized-triple-blind-controlled-trial
#10
Mahnaz Shahnazi, Azizeh Farshbaf-Khalili, Samira Pourzeinali-Beilankouh, Farnaz Sadrimehr
BACKGROUND: Combined oral contraceptives (COCs) have not been shown to have major effects on lipid and carbohydrate metabolism in normal-weight women. However, we have limited information about the effects on women at high risk for cardiovascular disease and diabetes due to being overweight and obese. OBJECTIVES: To evaluate the effects of second and third generation contraceptive pills on lipid and carbohydrate metabolism in overweight and obese women. PATIENTS AND METHODS: This triple-blind controlled trial was performed on 137 healthy women aged 18 - 40 years with a body mass index of 25-34...
September 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28142308/a-case-of-endometrial-carcinoma-in-a-long-term-levonorgestrel-intrauterine-system-lng-52%C3%A2-mg-ius-user
#11
Melisa Thomas, Paula Briggs
This report describes a 50-year-old woman who presented to a community gynaecology clinic complaining of persistent heavy vaginal bleeding with an LNG 52 mg-IUS in situ. She was subsequently found to have stage 1 grade 1a endometrioid carcinoma. From the literature, we have identified five similar cases. This case highlights the possibility of endometrial carcinoma despite treatment with an LNG 52 mg-IUS and reinforces the importance of investigating women who present with unusual persistent or heavy vaginal bleeding...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28140761/healthcare-provider-attitudes-regarding-contraception-for-women-with-obesity
#12
Tara C Jatlaoui, Lauren B Zapata, Kathryn M Curtis, Suzanne G Folger, Polly A Marchbanks, Michele G Mandel, Denise J Jamieson
BACKGROUND: Whether providers who regularly provide family planning services consider contraceptive methods as unsafe for women with obesity is unknown. METHODS: We analyzed questionnaire responses received from December 2009 to March 2010 from 635 office-based physicians and 1323 Title X clinic providers delivering family planning services, who were randomly sampled (response rate 65%) before the release of national evidence-based contraception guidelines. We examined provider and clinical setting characteristics and clinic patient demographics for association with provider misconceptions about safety of combined oral contraceptives (COCs), depot medroxyprogesterone acetate (DMPA), or intrauterine devices (IUDs) for women with obesity...
January 31, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28137405/contraception-for-adolescents-with-chronic-rheumatic-diseases
#13
Benito Lourenço, Katia T Kozu, Gabriela N Leal, Marco F Silva, Elisabeth G C Fernandes, Camila M P França, Fernando H C Souza, Clovis A Silva
Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies...
January 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28126541/temporary-removal-pharmacokinetics-of-levonorgestrel-and-ulipristal-acetate-emergency-contraception-in-women-with-normal-and-obese-body-mass-index
#14
Piyapa Praditpan, Angie Hamouie, Cale N Basaraba, Renu Nandakumar, Serge Cremers, Anne R Davis, Carolyn L Westhoff
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
January 23, 2017: Contraception
https://www.readbyqxmd.com/read/28092737/complex-molecular-changes-induced-by-chronic-progestogens-exposure-in-roach-rutilus-rutilus
#15
Gabor Maasz, Zita Zrinyi, Peter Takacs, Sandor Lovas, Istvan Fodor, Tibor Kiss, Zsolt Pirger
In our previous study, we measured 0.23-13.67ng/L progestogens (progesterone, drospirenone, levonorgestrel) in natural waters in the catchment area of the largest shallow lake of Central Europe, Lake Balaton. Progestogen contaminations act as potent steroids with mixed progestagenic, androgenic and mild estrogenic effects that is why our aim was to investigate the morphological and molecular effects of mixture of progesterone, drospirenone, and levonorgestrel in environmentally relevant (10ng/L) and higher (50 and 500ng/L) exposure concentrations in common roach, Rutilus rutilus...
January 13, 2017: Ecotoxicology and Environmental Safety
https://www.readbyqxmd.com/read/28088496/endogenous-thrombin-potential-changes-during-the-first-cycle-of-oral-contraceptive-use
#16
Carolyn L Westhoff, Malcolm C Pike, Serge Cremers, Andrew Eisenberger, Stella Thomassen, Jan Rosing
OBJECTIVES: Venous thromboembolism (VTE) risk increases within months of combination oral contraceptive (COC) initiation. Because elevated endogenous thrombin potential (ETP) has been found in several studies to be a VTE risk factor, we evaluated the extent of ETP changes during the initial cycle of an ethinyl estradiol (EE) and levonorgestrel (LNG) COC. We also assessed the relationship between ETP changes and systemic EE and LNG concentrations. STUDY DESIGN: Participants provided multiple blood samples during a first 21-day cycle of a 30-mcg EE/150-mcg LNG COC and after a further 7 days without an active COC...
January 11, 2017: Contraception
https://www.readbyqxmd.com/read/28087972/lack-of-effect-of-oral-cabotegravir-on-the-pharmacokinetics-of-a-levonorgestrel-ethinyl-estradiol-containing-oral-contraceptive-in-healthy-adult-females
#17
C Trezza, S L Ford, E Gould, Y Lou, C Huang, J M Ritter, A M Buchanan, W Spreen, P Patel
AIM(S): This study aimed to investigate whether cabotegravir (CAB), an integrase inhibitor in development for treatment and prevention of HIV-1, influences the pharmacokinetics (PK) of a levonorgestrel (LNG) and ethinyl estradiol (EE)-containing oral contraceptive (OC) in healthy women. METHODS: In this open-label, fixed-sequence crossover study, healthy female subjects received LNG 0.15 mg/EE 0.03 mg tablet once daily Days 1-10 alone and with oral CAB 30 mg once daily Days 11-21...
January 14, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28041992/changes-in-body-composition-in-women-using-long-acting-reversible-contraception
#18
Priscilla de Nazaré Silva Dos Santos, Tessa Madden, Karen Omvig, Jeffrey F Peipert
OBJECTIVE: Users of hormonal long-acting reversible contraception (LARC) report weight gain as a side effect, but few studies have assessed body composition change among LARC users. We evaluated weight and body composition of healthy women using the levonorgestrel intrauterine system (LNG-IUS), copper intrauterine device (copper IUD) or etonogestrel implant (ENG implant). We hypothesized that weight gain and body composition over 12 months would not differ between copper IUD, LNG-IUS and ENG implant users...
December 30, 2016: Contraception
https://www.readbyqxmd.com/read/28041990/estimating-systemic-exposure-to-levonorgestrel-from-an-oral-contraceptive
#19
Cale N Basaraba, Carolyn L Westhoff, Malcolm C Pike, Renu Nandakumar, Serge Cremers
OBJECTIVE: The gold standard for measuring oral contraceptive (OC) pharmacokinetics is the 24-h steady-state area under the curve (AUC). We conducted this study to assess whether limited sampling at steady state or measurements following use of one or two OCs could provide an adequate proxy in epidemiological studies for the progestin 24-h steady-state AUC of a particular OC. STUDY DESIGN: We conducted a 13-sample, 24-h pharmacokinetic study on both day 1 and day 21 of the first cycle of a monophasic OC containing 30-mcg ethinyl estradiol and 150-mcg levonorgestrel (LNG) in 17 normal-weight healthy White women and a single-dose 9-sample study of the same OC after a 1-month washout...
December 30, 2016: Contraception
https://www.readbyqxmd.com/read/28012273/timing-of-insertion-of-levonorgestrel-releasing-intrauterine-system-a-randomised-controlled-trial
#20
Pahh van der Heijden, Pmaj Geomini, M C Herman, S Veersema, M Y Bongers
OBJECTIVE: The objective was to assess whether patient-perceived pain during the insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) depends on the timing during the menstrual cycle. DESIGN: A stratified two-armed non-inferiority randomised controlled trial. SETTING: Large teaching hospital in Veldhoven, the Netherlands. SAMPLE: From October 2013 to May 2014, 60 nulliparous and 60 multiparous women were randomised...
January 2017: BJOG: An International Journal of Obstetrics and Gynaecology
keyword
keyword
20950
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"